Getty Images announced it will release its third quarter 2026 financial results after market close on November 16, 2026. The company will not hold a conference call or webcast due to its ongoing Chapter 11 restructuring process. This release is significant as it reflects Getty Images' efforts to maintain transparency during financial reorganization. Investors should watch for details on the company's performance and restructuring progress in the upcoming report.
Getty Images' upcoming third quarter 2026 financial results provide context for readers interested in market conditions. For those following the Media sector, here is Pluang's snapshot as of Nov 06, 2026 20:21 WIB: Among 57 priced US Media stocks, 21 rose and 32 fell. EchoStar Corporation outperformed with a 4.16% gain at USD 93.66 and a typical hold time of 10 days, contrasting with Telus Corporation's 4.78% drop to USD 8.97 and Vodafone Group's 3.70% decline to USD 15.36, both held longer on average.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
